In Vivo Assays

Oncology Animal Models

PerkinElmer's Contract Research Services has established a wide range of animal models in oncology for preclinical cancer research studies including syngeneic/xenogeneic, orthotopic/heterotopic, and primary/metastatic models. These models are used to assess anticancer therapies over the course of treatment in vivo. All our studies are highly customizable with study protocols optimized to meet our clients’ study requirements (route of administration, treatment protocol, imaging schedule, etc.)

To conduct in vivo anticancer drug efficacy studies, PerkinElmer's Contract Research Services uses relevant bioluminescent (light-emitting) cancer cell lines implanted into immunocompromised or immunocompetent animals. Tumor growth/metastasis and drug efficacy is monitored throughout the duration of the study using PerkinElmer's proprietary real-time in vivo imaging IVIS platform. The non-invasive optical bioluminescence/fluorescence IVIS technology increases the throughput of in vivo efficacy studies since it requires fewer test animals and shorter timelines compared to conventional animal testing paradigms. The combination of bioluminescent cancer cell lines and the IVIS platform enables us to perform longitudinal evaluation of tumor development and to monitor the efficacy of drug compounds on tumor growth while offering more and higher quality data. As such, more accurate and clinically relevant predictions can be made earlier in preclinical drug development process.

The recombinant luciferase cell lines used at PerkinElmer's Contract Research Services to establish oncology animal models may have various origins: i) PerkinElmer's Bioware portfolio of cell lines, ii) Custom recombinant cell lines developed by PerkinElmer's Contract Research Services or iii) Cell lines directly provided by clients. At PerkinElmer's Contract Research Services we offer:

The following table is a listing including our oncology animal models. At PerkinElmer's Contract Research Services we are also capable of developing any custom oncology model using our over 60

bioluminescent and fluorescent recombinant cell lines, client provided cell lines, or cell lines created by PerkinElmer's Contract Research Services from a parental cell line of interest.

Model Model/Application Animal Host Options Tumor Graft Cell Line Drug Injection Xenogeneic Anticancer Activity NIH-IIInu/bg (nude/beige) Subcutaneous i.v., i.p.

  • HT-29
  • NCI-H460
  • MDA-MB-231
  • MCF-7 (ER+)
  • MB-231 (ER-)
  • LNCaP

Xenogeneic NIH-IIInu/bg (nude/beige) Orthotopic/Primary i.v., i.p.

  • Colon Cancer Colon HT-29
  • Lung Cancer Lung NCI-H460
  • Breast Cancer Breast MDA-MB-231
  • Breast Cancer Breast MCF-7 (ER+)
  • Breast Cancer Breast MB-231 (ER-)

Xenogeneic NIH-IIInu/bg (nude/beige) Intravenous Metastasis i.v.

  • organs/tissues with metastasis HT-29
  • organs/tissues with metastasis NCI-H460

Syngeneic Orthotopic/Primary i.v., i.p.

  • Immunotox C57BL6 Skin B16F10
  • Immunotox BALBc Breast 4T1
Model
Model/
Application
Animal
Host
Options
Tumor
Graft
Cell
Line
Drug Injection
XenogeneicAnticancer ActivityNIH-IIInu/bg (nude/beige)Subcutaneous i.v., i.p.
     HT-29 
     NCI-H460 
     MDA-MB-231 
     MCF-7 (ER+) 
     MB-231 (ER-) 
     LNCaP 
Model
Model/
Application
Animal
Host
Options
Tumor Graft
Cell
Line
Drug Injection
Xenogeneic NIH-IIInu/bg (nude/beige) Orthotopic/
Primary		 i.v., i.p.
 Colon Cancer  Colon HT-29  
Lung CancerLungNCI-H460
 Breast Cancer  Breast MDA-MB-231 
Breast Cancer BreastMCF-7 (ER+)
 Breast Cancer  Breast MB-231 (ER-) 
Model
Model/
Application
Animal
Host
Options
Tumor
Graft
Cell Line
Drug Injection
Xenogeneic  NIH-IIInu/bg (nude/beige)  Intravenous Metastasis  i.v.
   organs/tissues with metastasis HT-29 
   organs/tissues with metastasis NCI-H460 
Model
Model/
Application
Animal
Host
Options
Tumor
Graft
Cell
Line
Drug Injection
Syngeneic  Orthotopic/Primary i.v., i.p.
  ImmunotoxC57BL6  Skin B16F10 
  Immunotox BALBc Breast 4T1